KMT5A and Miyoshi myopathy: Finally, the combination of UNC-0379 with the cytotoxic agent melphalan strongly enhances DNA damage and overcomes drug resistance, suggesting that targeting SETD8 activity could be beneficial to improve MM treatment in high-risk patients independently of their mutational status for p53.